1-[4-(1H-pyrazol-1-yl)benzyl]-8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 1216947-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-[4-(1H-pyrazol-1-yl)benzyl]-8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 8-Fluoro-4-oxo-1-[(4-pyrazol-1-ylphenyl)methyl]quinoline-3-carboxylic acid
• CAS: 1216947-01-1
• 化学式: C₂₀H₁₄FN₃O₃
• 分子量: 363.348
• InChiKey: SXJIWRKGAFTXQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  75.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (1R,2R)-反式-2-氨基环戊醇 盐酸盐 、 1-[4-(1H-pyrazol-1-yl)benzyl]-8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以0.11 g的产率得到8-fluoro-N-[(1,2-trans)-2-hydroxycyclopentyl]-4-oxo-1-[4-(1H-pyrazol-1-yl)benzyl]-1,4-dihydroquinoline-3-carboxamide
  参考文献：
  名称：

  DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR

  摘要：

  公开号：

  EP2821401B1
• 作为产物：
  描述：

  在 lithium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-[4-(1H-pyrazol-1-yl)benzyl]-8-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  N-Heterocyclic derived M1 positive allosteric modulators

  摘要：

  Replacement of a phenyl ring with N-linked heterocycles in a series of quinolone carboxylic acid M-1 positive allosteric modulators was investigated. In particular, a pyrazole derivative exhibited improvements in potency, free fraction, and CNS exposure. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.013

文献信息

• HETEROCYCLIC COMPOUND AND USE THEREFOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20150126487A1

  公开（公告）日：2015-05-07

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, a sleep disorder and the like. The present invention relates to a compound represented by the formula (I): wherein R 1 is an optionally substituted amino group or an optionally substituted cyclic amino group, R 2 and R 3 are each independently a hydrogen atom or a substituent, X is —CH═ or —N═, and ring A is an optionally substituted 5- to 10-membered ring, or a salt thereof.

  本发明提供了一种具有胆碱能肌动蛋白M1受体正变构调节剂活性的化合物，可用作预防或治疗阿尔茨海默病、精神分裂症、疼痛、睡眠障碍等药物。本发明涉及一种由式(I)表示的化合物：其中R1是可选取代的氨基或可选取代的环状氨基，R2和R3各自独立地是氢原子或取代基，X是—CH═或—N═，环A是可选取代的5-至10-成员环，或其盐。
• US9403802B2
  申请人：——

  公开号：US9403802B2

  公开（公告）日：2016-08-02
• N-Heterocyclic derived M1 positive allosteric modulators
  作者：Scott D. Kuduk、Christina N. Di Marco、Victoria Cofre、Daniel R. Pitts、William J. Ray、Lei Ma、Marion Wittmann、Lone Veng、Matthew A. Seager、Kenneth Koeplinger、Charles D. Thompson、George D. Hartman、Mark T. Bilodeau

  DOI：10.1016/j.bmcl.2010.01.013

  日期：2010.2

  Replacement of a phenyl ring with N-linked heterocycles in a series of quinolone carboxylic acid M-1 positive allosteric modulators was investigated. In particular, a pyrazole derivative exhibited improvements in potency, free fraction, and CNS exposure. (C) 2010 Elsevier Ltd. All rights reserved.
• DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2821401B1

  公开（公告）日：2020-09-09